Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism

Asthma is associated with increased airway smooth muscle (ASM) mass with increased disease severity and impaired lung function. The prostaglandin D2 (PGD2) receptor 2 (DP2) antagonist, fevipiprant, reduces airway eosinophilia and improves epithelial integrity, lung function, ACQ and AQLQ.

Chi tiết về thư mục
Những tác giả chính:	Saunders, R, Kaul, H, Berair, R, Singapuri, A, Chernyavsky, I, Chachi, L, Biddle, M, Utcliffe, A, Laurencin, M, Bacher, G, Bourne, M, Pavord, I, Wardlaw, A, Siddiqui, S, Kay, R, Brook, B, Smallwood, R, Brightling, C
Định dạng:	Conference item
Được phát hành:	European Respiratory Society 2017

Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism

Những quyển sách tương tự